Mesenchymal stem cell-derived CCL-9 and CCL-5 promote mammary tumor cell invasion and the activation of matrix metalloproteinases

References

• Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 2010; 18:884 - 901; http://dx.doi.org/10.1016/j.devcel.2010.05.012; PMID: 20627072
   PubMed Web of Science ®Google Scholar
• Pérez-Moreno M. When neighbourhood matters: tumour microenvironment. Clin Transl Oncol 2009; 11:70 - 4; http://dx.doi.org/10.1007/s12094-009-0316-z; PMID: 19211370
   PubMed Web of Science ®Google Scholar
• Mareel M, Oliveira MJ, Madani I. Cancer invasion and metastasis: interacting ecosystems. Virchows Arch 2009; 454:599 - 622; http://dx.doi.org/10.1007/s00428-009-0784-0; PMID: 19471961
   PubMed Web of Science ®Google Scholar
• Walter M, Liang S, Ghosh S, Hornsby PJ, Li R. Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells. Oncogene 2009; 28:2745 - 55; http://dx.doi.org/10.1038/onc.2009.130; PMID: 19483720
   PubMed Web of Science ®Google Scholar
• Mishra P, Banerjee D, Ben-Baruch A. Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. J Leukoc Biol 2011; 89:31 - 9; http://dx.doi.org/10.1189/jlb.0310182; PMID: 20628066
   PubMed Web of Science ®Google Scholar
• Jotzu C, Alt E, Welte G, Li J, Hennessy BT, Devarajan E, et al. Adipose tissue-derived stem cells differentiate into carcinoma-associated fibroblast-like cells under the influence of tumor-derived factors. Anal Cell Pathol (Amst) 2010; 33:61 - 79; PMID: 20978328
   PubMed Web of Science ®Google Scholar
• Pupa SM, Ménard S, Forti S, Tagliabue E. New insights into the role of extracellular matrix during tumor onset and progression. J Cell Physiol 2002; 192:259 - 67; http://dx.doi.org/10.1002/jcp.10142; PMID: 12124771
   PubMed Web of Science ®Google Scholar
• Calorini L, Bianchini F. Environmental control of invasiveness and metastatic dissemination of tumor cells: the role of tumor cell-host cell interactions. Cell Commun Signal 2010; 8:24; PMID: 20822533
   PubMed Web of Science ®Google Scholar
• Slettenaar VI, Wilson JL. The chemokine network: a target in cancer biology?. Adv Drug Deliv Rev 2006; 58:962 - 74; http://dx.doi.org/10.1016/j.addr.2006.03.012; PMID: 16996642
   PubMed Web of Science ®Google Scholar
• Dubinett SM, Lee JM, Sharma S, Mulé JJ. Chemokines: can effector cells be redirected to the site of the tumor?. Cancer J 2010; 16:325 - 35; http://dx.doi.org/10.1097/PPO.0b013e3181eb33bc; PMID: 20693843
   PubMed Web of Science ®Google Scholar
• Hembruff SL, Cheng N. Chemokine signaling in cancer: Implications on the tumor microenvironment and therapeutic targeting. Cancer Ther 2009; 7:A 254 - 67; PMID: 20651940
   PubMedGoogle Scholar
• Beider K, Abraham M, Peled A. Chemokines and chemokine receptors in stem cell circulation. Front Biosci 2008; 13:6820 - 33; http://dx.doi.org/10.2741/3190; PMID: 18508696
   PubMed Web of Science ®Google Scholar
• Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, Balkwill FR. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 2003; 63:8360 - 5; PMID: 14678997
   PubMed Web of Science ®Google Scholar
• Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449:557 - 63; http://dx.doi.org/10.1038/nature06188; PMID: 17914389
   PubMed Web of Science ®Google Scholar
• Pinilla S, Alt E, Abdul Khalek FJ, Jotzu C, Muehlberg F, Beckmann C, et al. Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer cell invasion. Cancer Lett 2009; 284:80 - 5; http://dx.doi.org/10.1016/j.canlet.2009.04.013; PMID: 19427114
   PubMed Web of Science ®Google Scholar
• Albarenque SM, Zwacka RM, Mohr A. Both human and mouse mesenchymal stem cells promote breast cancer metastasis. Stem Cell Res 2011; 7:163 - 71; http://dx.doi.org/10.1016/j.scr.2011.05.002; PMID: 21763624
   PubMed Web of Science ®Google Scholar
• Lv D, Zhang Y, Kim HJ, Zhang L, Ma X. CCL5 as a potential immunotherapeutic target in triple-negative breast cancer. Cell Mol Immunol 2013; In press http://dx.doi.org/10.1038/cmi.2012.69; PMID: 23376885
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yao F, Yao X, Yi C, Tan C, Wei L, et al. Role of CCL5 in invasion, proliferation and proportion of CD44+/CD24- phenotype of MCF-7 cells and correlation of CCL5 and CCR5 expression with breast cancer progression. Oncol Rep 2009; 21:1113 - 21; PMID: 19288016
   PubMed Web of Science ®Google Scholar
• Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Lifshitz-Mercer B, et al. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 1999; 59:4681 - 7; PMID: 10493525
   PubMed Web of Science ®Google Scholar
• Zhang J, Patel L, Pienta KJ. Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. Prog Mol Biol Transl Sci 2010; 95:31 - 53; http://dx.doi.org/10.1016/B978-0-12-385071-3.00003-4; PMID: 21075328
   PubMed Web of Science ®Google Scholar
• Zhang J, Patel L, Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev 2010; 21:41 - 8; http://dx.doi.org/10.1016/j.cytogfr.2009.11.009; PMID: 20005149
   PubMed Web of Science ®Google Scholar
• Hembruff SL, Jokar I, Yang L, Cheng N. Loss of transforming growth factor-beta signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage-dependent and -independent mechanisms. Neoplasia 2010; 12:425 - 33; PMID: 20454514
   PubMed Web of Science ®Google Scholar
• Lapteva N, Huang XF. CCL5 as an adjuvant for cancer immunotherapy. Expert Opin Biol Ther 2010; 10:725 - 33; http://dx.doi.org/10.1517/14712591003657128; PMID: 20233026
   PubMed Web of Science ®Google Scholar
• Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 2008; 267:271 - 85; http://dx.doi.org/10.1016/j.canlet.2008.03.018; PMID: 18439751
   PubMed Web of Science ®Google Scholar
• Murooka TT, Rahbar R, Fish EN. CCL5 promotes proliferation of MCF-7 cells through mTOR-dependent mRNA translation. Biochem Biophys Res Commun 2009; 387:381 - 6; http://dx.doi.org/10.1016/j.bbrc.2009.07.035; PMID: 19607806
   PubMed Web of Science ®Google Scholar
• Kroeze KL, Jurgens WJ, Doulabi BZ, van Milligen FJ, Scheper RJ, Gibbs S. Chemokine-mediated migration of skin-derived stem cells: predominant role for CCL5/RANTES. J Invest Dermatol 2009; 129:1569 - 81; http://dx.doi.org/10.1038/jid.2008.405; PMID: 19122644
   PubMed Web of Science ®Google Scholar
• Forst B, Hansen MT, Klingelhöfer J, Møller HD, Nielsen GH, Grum-Schwensen B, et al. Metastasis-inducing S100A4 and RANTES cooperate in promoting tumor progression in mice. PLoS One 2010; 5:e10374; http://dx.doi.org/10.1371/journal.pone.0010374; PMID: 20442771
   PubMed Web of Science ®Google Scholar
• Kitamura T, Taketo MM. Keeping out the bad guys: gateway to cellular target therapy. Cancer Res 2007; 67:10099 - 102; http://dx.doi.org/10.1158/0008-5472.CAN-07-2100; PMID: 17974948
   PubMed Web of Science ®Google Scholar
• Kitamura T, Fujishita T, Loetscher P, Revesz L, Hashida H, Kizaka-Kondoh S, et al. Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model. Proc Natl Acad Sci U S A 2010; 107:13063 - 8; http://dx.doi.org/10.1073/pnas.1002372107; PMID: 20616008
   PubMed Web of Science ®Google Scholar
• Soria G, Yaal-Hahoshen N, Azenshtein E, Shina S, Leider-Trejo L, Ryvo L, et al. Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions. Cytokine 2008; 44:191 - 200; http://dx.doi.org/10.1016/j.cyto.2008.08.002; PMID: 18790652
   PubMed Web of Science ®Google Scholar
• Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2:161 - 74; http://dx.doi.org/10.1038/nrc745; PMID: 11990853
   PubMed Web of Science ®Google Scholar
• Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 2004; 16:558 - 64; http://dx.doi.org/10.1016/j.ceb.2004.07.010; PMID: 15363807
   PubMed Web of Science ®Google Scholar
• Herman JG, Stadelman HL, Roselli CE. Curcumin blocks CCL2-induced adhesion, motility and invasion, in part, through down-regulation of CCL2 expression and proteolytic activity. Int J Oncol 2009; 34:1319 - 27; PMID: 19360344
   PubMed Web of Science ®Google Scholar
• Adler EP, Lemken CA, Katchen NS, Kurt RA. A dual role for tumor-derived chemokine RANTES (CCL5). Immunol Lett 2003; 90:187 - 94; http://dx.doi.org/10.1016/j.imlet.2003.09.013; PMID: 14687724
   PubMed Web of Science ®Google Scholar
• Murooka TT, Rahbar R, Platanias LC, Fish EN. CCL5-mediated T-cell chemotaxis involves the initiation of mRNA translation through mTOR/4E-BP1. Blood 2008; 111:4892 - 901; http://dx.doi.org/10.1182/blood-2007-11-125039; PMID: 18337562
   PubMed Web of Science ®Google Scholar
• Stormes KA, Lemken CA, Lepre JV, Marinucci MN, Kurt RA. Inhibition of metastasis by inhibition of tumor-derived CCL5. Breast Cancer Res Treat 2005; 89:209 - 12; http://dx.doi.org/10.1007/s10549-004-5328-3; PMID: 15692764
   PubMed Web of Science ®Google Scholar
• Vosseler S, Lederle W, Airola K, Obermueller E, Fusenig NE, Mueller MM. Distinct progression-associated expression of tumor and stromal MMPs in HaCaT skin SCCs correlates with onset of invasion. Int J Cancer 2009; 125:2296 - 306; http://dx.doi.org/10.1002/ijc.24589; PMID: 19610062
   PubMed Web of Science ®Google Scholar
• Zhao T, Harada H, Teramura Y, Tanaka S, Itasaka S, Morinibu A, et al. A novel strategy to tag matrix metalloproteinases-positive cells for in vivo imaging of invasive and metastatic activity of tumor cells. J Control Release 2010; 144:109 - 14; http://dx.doi.org/10.1016/j.jconrel.2010.01.023; PMID: 20096316
   PubMed Web of Science ®Google Scholar
• Joo CK, Seomun Y. Matrix metalloproteinase (MMP) and TGF beta 1-stimulated cell migration in skin and cornea wound healing. Cell Adh Migr 2008; 2:252 - 3; http://dx.doi.org/10.4161/cam.2.4.6772; PMID: 19262153
   PubMed Web of Science ®Google Scholar
• Krause S, Maffini MV, Soto AM, Sonnenschein C. A novel 3D in vitro culture model to study stromal-epithelial interactions in the mammary gland. Tissue Eng Part C Methods 2008; 14:261 - 71; http://dx.doi.org/10.1089/ten.tec.2008.0030; PMID: 18694322
   PubMed Web of Science ®Google Scholar
• Horning JL, Sahoo SK, Vijayaraghavalu S, Dimitrijevic S, Vasir JK, Jain TK, et al. 3-D tumor model for in vitro evaluation of anticancer drugs. Mol Pharm 2008; 5:849 - 62; http://dx.doi.org/10.1021/mp800047v; PMID: 18680382
   PubMed Web of Science ®Google Scholar
• Kim JB, Stein R, O’Hare MJ. Three-dimensional in vitro tissue culture models of breast cancer-- a review. Breast Cancer Res Treat 2004; 85:281 - 91; http://dx.doi.org/10.1023/B:BREA.0000025418.88785.2b; PMID: 15111767
   PubMed Web of Science ®Google Scholar
• Bland E, Dréau D, Burg KJ. Overcoming hypoxia to improve tissue-engineering approaches to regenerative medicine. J Tissue Eng Regen Med 2012; In press http://dx.doi.org/10.1002/term.540; PMID: 22761177
   PubMed Web of Science ®Google Scholar
• Carlson J, Baxter SA, Dréau D, Nesmelova IV. The heterodimerization of platelet-derived chemokines. Biochim Biophys Acta 2013; 1834:158 - 68; http://dx.doi.org/10.1016/j.bbapap.2012.09.010; PMID: 23009808
   PubMed Web of Science ®Google Scholar
• Lance A, Yang C-C, Swamydas M, Dean D, Deitch S, Burg KJ, et al. Increased extracellular matrix density decreases MCF10A breast cell acinus formation in 3D culture conditions. J Tissue Eng Regen Med 2013; In press http://dx.doi.org/10.1002/term.1675; PMID: 23404906
   PubMedGoogle Scholar
• Swamydas M, Eddy JM, Burg KJ, Dréau D. Matrix compositions and the development of breast acini and ducts in 3D cultures. In Vitro Cell Dev Biol Anim 2010; 46:673 - 84; http://dx.doi.org/10.1007/s11626-010-9323-1; PMID: 20585895
   PubMed Web of Science ®Google Scholar
• Zhao M, Dumur CI, Holt SE, Beckman MJ, Elmore LW. Multipotent adipose stromal cells and breast cancer development: Think globally, act locally. Mol Carcinog 2010; 49:923 - 7; http://dx.doi.org/10.1002/mc.20675; PMID: 20842668
   PubMed Web of Science ®Google Scholar
• Udagawa T, Wood M. Tumor-stromal cell interactions and opportunities for therapeutic intervention. Curr Opin Pharmacol 2010; 10:369 - 74; http://dx.doi.org/10.1016/j.coph.2010.06.010; PMID: 20638903
   PubMed Web of Science ®Google Scholar
• Kuhn NZ, Tuan RS. Regulation of stemness and stem cell niche of mesenchymal stem cells: implications in tumorigenesis and metastasis. J Cell Physiol 2010; 222:268 - 77; http://dx.doi.org/10.1002/jcp.21940; PMID: 19847802
   PubMed Web of Science ®Google Scholar
• Coghlin C, Murray GI. Current and emerging concepts in tumour metastasis. J Pathol 2010; 222:1 - 15; http://dx.doi.org/10.1002/path.2727; PMID: 20681009
   PubMed Web of Science ®Google Scholar
• Sharma M. Chemokines and their receptors: orchestrating a fine balance between health and disease. Crit Rev Biotechnol 2010; 30:1 - 22; http://dx.doi.org/10.3109/07388550903187418; PMID: 19780653
   PubMed Web of Science ®Google Scholar
• Liu J, Merritt JR. CC chemokine receptor small molecule antagonists in the treatment of rheumatoid arthritis and other diseases: a current view. Curr Top Med Chem 2010; 10:1250 - 67; http://dx.doi.org/10.2174/156802610791561192; PMID: 20536422
   PubMed Web of Science ®Google Scholar
• Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M, et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res 2002; 62:1093 - 102; PMID: 11861388
   PubMed Web of Science ®Google Scholar
• Kiss DL, Longden J, Fechner GA, Avery VM. The functional antagonist Met-RANTES: a modified agonist that induces differential CCR5 trafficking. Cell Mol Biol Lett 2009; 14:537 - 47; http://dx.doi.org/10.2478/s11658-009-0017-1; PMID: 19448977
   PubMed Web of Science ®Google Scholar
• Velasco-Velázquez M, Jiao X, De La Fuente M, Pestell TG, Ertel A, Lisanti MP, et al. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res 2012; 72:3839 - 50; http://dx.doi.org/10.1158/0008-5472.CAN-11-3917; PMID: 22637726
   PubMed Web of Science ®Google Scholar
• Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia 2010; 15:201 - 12; http://dx.doi.org/10.1007/s10911-010-9177-x; PMID: 20440544
   PubMed Web of Science ®Google Scholar
• Cai KQ, Yang WL, Capo-Chichi CD, Vanderveer L, Wu H, Godwin AK, et al. Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis. Mol Carcinog 2007; 46:130 - 43; http://dx.doi.org/10.1002/mc.20273; PMID: 17131304
   PubMed Web of Science ®Google Scholar
• Martin MD, Matrisian LM. The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev 2007; 26:717 - 24; http://dx.doi.org/10.1007/s10555-007-9089-4; PMID: 17717634
   PubMed Web of Science ®Google Scholar
• Fields GB. Using fluorogenic peptide substrates to assay matrix metalloproteinases. Methods Mol Biol 2010; 622:393 - 433; http://dx.doi.org/10.1007/978-1-60327-299-5_24; PMID: 20135296
   PubMedGoogle Scholar
• Miller MA, Barkal L, Jeng K, Herrlich A, Moss M, Griffith LG, et al. Proteolytic Activity Matrix Analysis (PrAMA) for simultaneous determination of multiple protease activities. Integr Biol (Camb) 2011; 3:422 - 38; http://dx.doi.org/10.1039/c0ib00083c; PMID: 21180771
   PubMed Web of Science ®Google Scholar
• Robinson SC, Scott KA, Balkwill FR. Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-alpha. Eur J Immunol 2002; 32:404 - 12; http://dx.doi.org/10.1002/1521-4141(200202)32:2<404::AID-IMMU404>3.0.CO;2-X; PMID: 11813159
   PubMed Web of Science ®Google Scholar
• Prest SJ, Rees RC, Murdoch C, Marshall JF, Cooper PA, Bibby M, et al. Chemokines induce the cellular migration of MCF-7 human breast carcinoma cells: subpopulations of tumour cells display positive and negative chemotaxis and differential in vivo growth potentials. Clin Exp Metastasis 1999; 17:389 - 96; http://dx.doi.org/10.1023/A:1006657109866; PMID: 10651305
   PubMed Web of Science ®Google Scholar
• Mousseau Y, Leclers D, Faucher-Durand K, Cook-Moreau J, Lia-Baldini AS, Rigaud M, et al. Improved agarose gel assay for quantification of growth factor-induced cell motility. Biotechniques 2007; 43:509 - 16; http://dx.doi.org/10.2144/000112557; PMID: 18019343
   PubMed Web of Science ®Google Scholar
• Elsner J, Petering H, Höchstetter R, Kimmig D, Wells TN, Kapp A, et al. The CC chemokine antagonist Met-RANTES inhibits eosinophil effector functions through the chemokine receptors CCR1 and CCR3. Eur J Immunol 1997; 27:2892 - 8; http://dx.doi.org/10.1002/eji.1830271122; PMID: 9394815
   PubMed Web of Science ®Google Scholar